Fabrizio Virgili

Dr. Fabrizio Virgili

Sapienza University of Rome, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
Fabrizio VirgiliFabrizio Virgili
Fabrizio Virgili
RNRaffaella Nenna
Raffaella Nenna
SDShira Ben David
Shira Ben David
MEMancino Enrica
Mancino Enrica
GMGreta Di Mattia
Greta Di Mattia
Fabio MidullaFabio Midulla
Fabio Midulla
The use of electronic cigarettes (e-cigarette) and vaping devices started as a potential aid for cessation and reducing the harmful consequences of cigarette smoking, mainly in the adult population. Today e-cigarette use is highly increasing in vulnerable populations, especially young and pregnant women, due to the misconception of its harmless use.Despite the growing acknowledgment in e-cigarette as a potential harmful device, and due to mixed information found concerning its beneficial aid for smokers, along with an insufficient clinical study done in human models, it is important to further evaluate the possible benefits and risks of non-combusting, vaping nicotine or non-nicotine delivery devices.In this review we tried to summarize the latest updated information found in the literature, concentrating mainly in the variety of adverse effects of e-cigarette use and its contribution for recent and future health concerns.

1 August 2024 in Current Pediatric Reviews
Verified
Journal Article
Closed access
PDF file
Fabrizio VirgiliFabrizio Virgili
Fabrizio Virgili
RNRaffaella Nenna
Raffaella Nenna
GMGreta Di Mattia
Greta Di Mattia
LMLuigi Matera
Luigi Matera
LPLaura Petrarca
Laura Petrarca
FMFabio Midulla
Fabio Midulla
Background: Acute bronchiolitis is a viral infection of the lower respiratory tract affect- ing infants aged under 12 months, variably presenting with respiratory distress, diffuse crackles and inflammatory wheezing. The main causative agent is Respiratory Syncytial Virus (RSV). The diagnosis is clinical and treatment mainly supportive. Despite the availability of more than 30 in- ternational guidelines, consistent management recommendations are lacking and considerable vari- ability in patients’ care persists among different providers. Objective: To review and describe current knowledge about epidemiology, physiopathology, clin- ic, diagnosis and management of acute bronchiolitis, with particular emphasis on updated evidence and future perspectives in terms of treatment and prevention. Methods and Results: We searched Cochrane for systematic reviews and PubMed for scientific ar- ticles published in the last 10 years, using a combination of the following search terms: “bronchi- olitis”, “respiratory syncytial virus”, “epidemiology”, “risk factors”, “severity”, “diagnosis”, “clin- ic”, “diagnostic imaging”, “management”, “asthma”, “wheezing”, “bronchodilator”, “steroids”, “hypertonic saline”, “oxygen”, “blood gas analysis”, “HHHFNC”, “rehydration”, “enteral feed- ing”, “parenteral hydration”, “prevention”, “vaccine” and “COVID-19 or SARS-CoV2”. We ac- cordingly performed a deep and extensive selection of the most updated and considerable litera- ture on the matter, summarizing the most significant evidence concerning all aspects of acute bron- chiolitis (epidemiology, clinic, diagnosis, management and prevention). Furthermore, we ex- amined references and available guidelines from UK, USA, Canada, Italy and Spain. Results are extensively discussed below. Conclusion: Although acute bronchiolitis has been a widely known disease for decades, its thera- peutic approach remained unchanged and essentially limited to respiratory and metabolic support. Despite the abundance of studies, there is no significant evidence concerning therapeutic alterna- tives (e.g. steroids, inhaled hypertonic solution), which are therefore not recommended. Accord- ing to most recent data, “acute bronchiolitis” definition encompasses a plethora of different clini- cal entities related to each subject’s genetic and immune predisposition. Therefore, future research should focus on the precise characterization of such subcategories in order to individualize thera- peutic management and ensure the most appropriate evidence-based care.

17 November 2025 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
Fabrizio VirgiliFabrizio Virgili
Fabrizio Virgili
FPFabiola Del Parco
Fabiola Del Parco
DRDomenico Paolo La Regina
Domenico Paolo La Regina
EMEnrica Mancino
Enrica Mancino
LPLaura Petrarca
Laura Petrarca
Fabio MidullaFabio Midulla
Fabio Midulla
Background: E-cigarettes and Heated Tobacco Products (HTPs), which emerged as “safer” alternatives to traditional cigarettes, remain easily accessible and widely misperceived as harmless, especially among adolescents. Our study aimed to assess the prevalence of e-cigarette and HTP use among Italian adolescents, and investigate underlying motivations, risk perceptions, and social influences. Methods: We conducted a cross-sectional survey among 200 adolescents aged 11–18 years. Participants completed a 50-item anonymous questionnaire exploring sociodemographic characteristics, smoking behaviors, reasons for use, risk awareness, and social influence. Results: Among participants, 23% reported using e-cigarettes and 16% HTPs. Disposable, flavored and nicotine-containing products were highly prevalent. Among vapers, use was significantly more frequent in those aged > 14 years, and in individuals reporting social influence, stress, or sadness/apathy. Similar patterns were observed among HTP users. Risk perception was low: 85% of participants believed e-smoking was less harmful than conventional smoking, and only 5% recognized e-cigarettes as significantly harmful. Only 20% of all participants had been asked about smoking during medical visits, with significantly lower rates among those < 14 years. A comprehensive analysis of usage patterns, psychosocial correlates, and risk perception is provided in the full manuscript. Conclusion: The underestimation of health risks associated with electronic smoking devices pose a serious Public Health challenge. Findings highlight the urgent need for targeted interventions combining stricter access control, enhanced risk communication, and integration of tobacco prevention into school and clinical settings. Greater attention should be paid to the psychological dimension of adolescent smoking and the evolving landscape of nicotine delivery systems.

8 August 2024 in Pediatric Reports
Verified
Journal Article
Open access
PDF file
Fabrizio VirgiliFabrizio Virgili
Fabrizio Virgili
Fabio MidullaFabio Midulla
Fabio Midulla
FBFernando Maria De Benedictis
Fernando Maria De Benedictis
Respiratory Syncytial Virus (RSV) is a medium-sized enveloped Pneumovirus belonging to the Paramyxoviridae family

1 March 2025 in Current Respiratory Medicine Reviews
Verified
Journal Article
Closed access
PDF file
Fabrizio VirgiliFabrizio Virgili
Fabrizio Virgili
SGStefano Guerra
Stefano Guerra
FMFabio Midulla
Fabio Midulla
FMFernando D. Martinez
Fernando D. Martinez
MHMarilyn Halonen
Marilyn Halonen
RNRaffaella Nenna
Raffaella Nenna
Cytomegalovirus (CMV) is a ubiquitous pathogen that causes asymptomatic infections in the healthy immunocompetent host but is responsible for severe disease in immunocompromised individuals, graft failure, and congenital disabilities. Recent research implicates CMV as a crucial determinant of immunosenescence (detrimental age-related alterations responsible for the decline of immune responsiveness) and, more generally, a marker of life expectancy. CMV serostatus has been linked to an increased risk of cardiovascular, respiratory, oncological, and non-specific mortality in a number of intriguing, if not entirely clear, studies. Through a deep and extensive selection of the most updated and relevant literature on the matter, we summarized the most significant evidence concerning the role of CMV in immunosenescence, as well as all-cause and disease-related mortality. As is widely known, viral infections play a substantial role in the development and progression of respiratory disorders and are a well-established trigger for their exacerbations. Consistent with current observations correlating CMV seropositivity to mortality by chronic pulmonary disease, in the second part of the review, we focused on CMV involvement in obstructive lung disorders. In light of available evidence, CMV serostatus could represent a useful biomarker for risk stratification or even an underestimated target in the pathogenesis of several diseases. Considering the somewhat conflicting results and the potential clinical implications for a direct role of CMV in multiple chronic diseases, including obstructive lung diseases, we hope the present work encourages further investigation on the topic.

1 March 2025 in Current Respiratory Medicine Reviews
Verified
Journal Article
Closed access
PDF file
Fabrizio VirgiliFabrizio Virgili
Fabrizio Virgili
DRDomenico La Regina
Domenico La Regina
RNRaffaella Nenna
Raffaella Nenna
EMEnrica Mancino
Enrica Mancino
LMLuigi Matera
Luigi Matera
FMFabio Midulla
Fabio Midulla
Background: Bronchiectases are structural alterations characterized by the dilation of bronchial walls due to inflammation, resulting in a loss of elasticity and muscle function. They are more common in adults than children and have various etiologies (such as chronic infections, particularly in developing countries, or immunodeficiencies in industrialized nations), with up to 40% being idiopathic. Case presentation: We reported the case of a nine-year-old child who, following two lower respiratory tract infections (a severe H1N1 influenza pneumonia and a milder episode caused by M. pneumoniae), developed bronchiectasis without underlying predisposing conditions. Discussion: Bronchiectasis is a morphological alteration of the bronchi, which can develop subsequently to lung infections and may remain clinically silent even for a long time. The most common associated symptoms include productive cough, persistent rales, therapy-resistant “asthma,” and recurrent lung infections. High-Resolution CT (HRCT) scans are the gold standard for their diagnosis, while their management requires a comprehensive approach, including pharmacological and psychosocial measures. It is always advisable to investigate the underlying etiology to eventually establish a causal treatment. Conclusion: This study aims to emphasize that not only bacteria but also viral infections and their associated inflammatory impact on lung tissue can contribute to the development of bronchiectasis. This study aims to implement current knowledge regarding non-cystic fibrosis-related bronchiectasis and to underscore the significance of post-acute instrumental reassessment in lower respiratory tract infections, especially when severe.